Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients ...
Alkermes plc, headquartered in Dublin, Ireland, is a fully integrated biopharmaceutical company dedicated to addressing unmet medical needs in neuroscience. Founded in 1987 by Michael Wall, the company has evolved into a leader in the development of therapies for conditions such as schizophrenia, bipolar I disorder, opioid dependence, alcohol dependence, and narcolepsy. Its proprietary commercial portfolio includes ARISTADA and ARISTADA INITIO for schizophrenia, VIVITROL for alcohol and opioid dependence, LYBALVI for schizophrenia and bipolar I disorder, and LUMRYZ for cataplexy or excessive daytime sleepiness. The company also leverages its proprietary technology platforms to collaborate with third parties, such as Janssen Pharmaceutica, to develop and commercialize additional products. Alkermes is committed to innovation, with a robust pipeline of clinical and preclinical candidates targeting neurological disorders. Financially, the company reported a market capitalization of approximately $8.25 billion as of the latest data, with a gross profit margin of 84.6% and a net profit margin of 4%. It employs over 2,000 people globally, with significant operations in Ireland and the United States. Under the leadership of CEO Richard Pops, who has been with the company for over three decades, Alkermes continues to drive growth through strategic initiatives, including the recent acquisition of Avadel's LUMRYZ and the planned separation of its oncology business to focus solely on neuroscience. The company's dedication to innovation and patient care positions it as a key player in the biopharmaceutical industry.
